Castle’s DecisionDx-Melanoma Test Can Identify Melanoma Patients with Low Risk of Sentinel Lymph Node Positivity Who Can Forego Biopsy
Castle Biosciences, Inc.’s DecisionDx-Melanoma can predict sentinel lymph node (SLN) positivity risk to help guide risk-aligned sentinel lymph node biopsy (SLNB) decisions, potentially reducing the number of unnecessary procedures and increasing the SLNB positivity yield if the procedure is performed, according to a new study in the World Journal of Surgical Oncology. DecisionDx-Melanoma is a […]